Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Conferences

Thumbnail
April 12, 2021

AACR 2021 roundup

Evaluate Vantage's coverage of the virtual AACR 2021 congress.

Thumbnail
April 10, 2021

AACR 2021 – still awaiting validation, Sanofi keeps on buying

The group does not let the grass grow under its feet, acquiring Tidal Therapeutics before its bigger Synthorx buy has proven itself.

Article image
Vantage logo
April 10, 2021

AACR 2021 – Affimed wins, Oncternal loses

Phase 1 results at this weekend’s virtual AACR show an unexpected win for Affimed’s AFM13 and a disappointing update from Oncternal.

Article image
Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

The most important of this year’s two virtual AACRs features immunotherapy combos, new Kras players and first clinical data for several assets.

Article image
Vantage logo
March 13, 2021

AD/PD 2021 – Donanemab has much still to prove

Full data on Lilly's Alzheimer’s antibody will disappoint some, and point to a long road ahead.

Article image
Vantage logo
March 10, 2021

Lilly lines up its next shot at Alzheimer’s

Expectations are high ahead of a detailed look at donanemab data, but hopes for a fast path to market feel overblown.

Article image
Vantage logo
February 13, 2021

Asco-GU – Clear blue water between Keytruda and kidney cancer rivals

Merck & Co/Eisai’s Clear study results look better than Bristol/Exelixis’s Checkmate-9ER, but the big loser could be Pfizer.

Article image
Vantage logo
February 12, 2021

Asco-GU – confirmatory Padcev trial throws a curveball

Subgroup analysis of a confirmatory US study in bladder cancer suggests no benefit in female patients.

Article image
Vantage logo
February 10, 2021

World Symposium – Orchard leads the crop of Hurler syndrome hopefuls

Promising early data with the group’s gene therapy put it ahead of Regenxbio for now.

Article image
Vantage logo
February 09, 2021

Asco-GU – Bristol in pole position with Opdivo’s adjuvant use

Bladder cancer is the fourth tumour type to give Opdivo a phase III adjuvant win, and the extent of the survival benefit is impressive.

Article image
Vantage logo
February 01, 2021

World Lung 2020 – amivantamab puts more data behind the hype

But how will the complex J&J bispecific antibody fare in a market where oral small molecules are the norm?

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.